Preferred injection sites The abdomen is the most common site, specifically the area around the navel but at least 2 inches away from it
Drugs 70, 20892112
Criteria for approval of GLP-1 medications: The medication is prescribed to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity

Modifications to the peptide chain to reduce degradation by DPP-4, combined with acylation to promote non-covalent binding to albumin, resulted in long-acting formulations, enabling their use in clinical practice.3,5 Initially, GLP-1 receptor monoagonists were marketed with the aim of treating type 2 diabetes, harnessing their incretin effect and glucose-dependent mechanism, along with their capacity to reduce body weight and their beneficial effects on associated comorbidities.1,3,5 Subsequently, research shifted its focus to obesity, employing higher doses than those used for diabetes.3,5 This was followed by the development of unimolecular structures with multi-receptor activity, such as GIP/GLP-1 and GLP-1/glucagon (GCG) coagonists, as well as GIP/GLP-1/GCG triagonists
Similarly, in the Peptide Innovation for Early Diabetes Treatment (PIONEER) clinical trial, oral semaglutide was tested in patients with DM2
Lost over 60 lbs *Personal results may vary based on our individualized health programs